Bronchiectasis
246
41
46
108
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
23 trials with published results (9%)
Research Maturity
108 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.3%
18 terminated out of 246 trials
85.7%
-0.8% vs benchmark
17%
42 trials in Phase 3/4
21%
23 of 108 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 108 completed trials
Clinical Trials (246)
Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases
HFNC in Management of Bronchiectasis Exacerbation
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Telerehabilitation in Patients With Bronchiectasis
Natural History of Bronchiectasis
OLE Therapy With BE Patients in Home Care Study
Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
Immune Status and Disease Control of Inflammatory Airway Diseases
Clinical Outcomes of BronchiEctaSis in Taiwan: A Multicenter Prospective Cohort (BEST Study)
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
Simeox 200 US Study
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
COMBO Endoscopy Oropharyngeal Airway in Sedated Fiberoptic Bronchoscopy for Patients: A Simon Two-Stage Trial
Mid-point Transverse Process to Pleura Block Versus Thoracic Paravertebral Block in Posterolateral Thoracotomy
A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Functional Inspiratory Training in Bronchiectasis
Itraconazole Therapy In Bronchiectasis With Airway Mold